Introduction
The etiology of most neuropsychiatric disorders is incompletely understood. In recent years the concept has emerged that for several disorders, including schizophrenia, their pivotal cause might be a dysregulation in synapto-dendritic morphogenesis during development. 1, 2 There is accumulating evidence that disturbances during neuronal differentiation and maturation processes in development can have profound effects on neuronal information processing in the adult despite the relatively mild morphological phenotypes in the affected brain regions. The most prevailing evidence for altered synapto-dendritic microcircuitry exists in schizophrenia (for reviews see Eastwood, 2004; 3 Lewis and Levitt, 2002; 4 McGlashan and Hoffman, 2000; 5 Woods, 1998 6 ). Interestingly, the aberrant wiring patterns observed in patients with chronic paranoid schizophrenia seem to be particularly prominent only in certain brain regions such as the prefrontal cortex. 3, 4, 7 The structural anomalies in schizophrenic patients include a region-and layer-specific reduction of spine synapses that concomitantly frequently exhibit an aberrant morphology, [8] [9] [10] [11] [12] [13] [14] [15] smaller dendritic fields and a decreased number of basilar dendrites in conjunction with simplified dendritic branching patterns. 8, 16, 17 In essence, the available data suggest that the wiring of circuitry is altered in schizophrenia 3, 5, 6, 15, 17, 18 and that the synaptic pathology might be causally related to abnormalities in dendrite morphology.
At present, it is not clear how these alterations were initially brought about during development and why no phenotypic correction occurred until adulthood. As the synaptic and dendritic aberrations in schizophrenia are relatively mild and not present in all brain regions, it is reasonable to assume that local changes at a limited number of synapses and dendrites are sufficient to trigger changes leading to disease development. According to preclinical and clinical data, an imbalance of dopamine and/or glutamate transmission in the striatum and/or the prefrontal cortex appears crucial in schizophrenia. 19, 20 The N-methyl-D-aspartate (NMDA) receptor is anchored to the postsynaptic density (PSD), a multiprotein meshwork of surface receptors, scaffolding proteins and intracellular effectors. Moreover, the PSD is a site of integration of glutamate and dopamine signaling by mechanisms of transactivation or convergence 21, 22 of intracellular pathways. Indeed, several PSD proteins have been associated with schizophrenia although the nature of their role is largely unclear. Interestingly, ketamine, a noncompetitive antagonist of NMDA receptors, is known to induce psychotomimetic effects in healthy volunteers and to re-exacerbate psychotic symptoms in chronic schizophrenic patients (Kristiansen et al. 23 and references therein). Due to the blockade of the NMDA receptor ion channel, ketamine is predicted to induce a state of NMDA receptor hypofunction. In this study, we analyzed systematically the synaptic proteome in the subchronic rat ketamine model of psychosis. 24, 25 To further validate the animal model we subsequently compared the data with a proteomic screen of a synaptic membrane fraction of the left dorsolateral prefrontal cortex (DPLFC) of patients suffering from chronic schizophrenia. To validate the approach we finally examined in more detail the expression of one protein, prohibitin, which was found to be dysregulated under both conditions.
Materials and methods

Human subjects
Case recruitment, acquisition of personal data, autopsy and handling of autoptic material has been approved by the responsible ethical committee. For prohibitin immunostainings post-mortem brains of eight patients with schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders, 2nd edn, revised (five men, three women) and seven matched control cases (five men, two women) were investigated (Supplementary Table 1 ). All brains were obtained from the New Magdeburg brain collection. Patients with schizophrenia and psychically healthy patients died between years 1988 and 1993. Age ranged from 38 to 63 years. A lifetime psychiatric diagnosis of schizophrenia was established according to DSM-III-R (American Psychiatric Association, 1987) by using the Diagnostic Instrument for brain studies, 26 a structured instrument for the collection of clinical, pharmacological and other relevant information from case histories. All patients with schizophrenia had histories of inpatient hospitalization. Only patients with well-documented and extensive clinical records were selected for the present study. Demographic data are summarized in Supplementary  Table 1 . The mean duration of illness was 18.3 years with a range from 8 to 34 years. The subtypes of schizophrenia according to DSM-III-R and other clinical characteristics are also presented in Supplementary Table 1 . Brain volumes were calculated by the weight method using fresh whole brain weight and brain density. 27 There were no significant differences (Student's t-test, w 2 -analysis) between patients with schizophrenia and controls with regard to age, gender and storage delay. For quantitative immunoblotting experiments, six shock-frozen tissue samples of the DPLFC were analyzed from schizophrenic and control patients, respectively (for details see Bernstein et al. 28 ). Two-dimensional (2D) gel electrophoresis was performed with DPLFC tissue samples from 10 schizophrenic and 15 control cases (for patient and treatment details, see Supplementary Table 2 ). All schizophrenic patients received antipsychotic drug medication during the course of their disease. Control brains of patients without a history of neuropsychiatric disorders were obtained from the same pathological institutes or medical examiner's office. Brains with lifetime reports of abuse of alcohol, drugs, dementia, neurological illness, trauma, chronic terminal disease known to affect the brain were excluded. In addition, quantitative neuropathological changes due to neurodegenerative disorders were ruled out by an experienced neuropathologist. 29 
Animal experiments
All experimental procedures were performed according to the National Institutes of Health guidelines for the care and use of laboratory animals and German law of animal welfare; they were approved by the local authorities. All rats were 12 weeks old when the experiments were started (weight: 250-300 g). Animals were kept on a 12/12 h dark-light cycle at a relative humidity of 50-60% and 22 1C with food and water available ad libitum. A total of eight rats were used for each experimental group. Ketamine psychosis was induced by the subchronic administration of the drug (30 mg kg À1 ) in male Sprague-Dawley rats (local breeding facilities of the Leibniz Institute for Neurobiology) as previously described. 24 Ketamine (Sigma-Aldrich, Munich, Germany ) was dissolved in 0.9% NaCl solution and administered intraperitoneally on 5 consecutive days. This treatment regime has been shown to induce psychosis-like behavior in rats for several weeks. 25 Control animals received the same number of saline injections under the same time regime as ketamine-treated rats. To control for potential effects of antipsychotic medication on prohibitin levels rats were subchronically administered with clozapine (Sigma-Aldrich). The rats received daily injections of the drug (5 mg per kg) for 14 days. Control rats were injected the corresponding volume of vehicle. Fourteen days after termination of ketamine or directly after termination of clozapine treatment, rats were anesthetized with halothane and decapitated. From the brains the cortical tissue was dissected and then further subjected to biochemical fractionation.
Biochemical fractionation and 2D gel electrophoresis
In order to obtain a fraction enriched for synaptic structures a protocol established previously 30 was used. Briefly, cortical tissue was homogenized in 10 mM Tris-HCl, pH 8.1 containing 0.5% Triton X-100 and protease inhibitors (Complete; Roche, Mannheim, Germany), incubated for 1 h and spun at 100 000 g for 1 h (Optima Ultracentrifuge; Beckman Coulter, Fullerton, CA, USA). The resulting pellet was rehomogenized in the same buffer and centrifuged again for 1 h at 100 000 g. Pellets were stored at À80 1C.
For 2D gel electrophoresis, samples were homogenized in lysis buffer (8 M urea, 4% 3[(3-cholamidopropyl)dimethylammonio]-propanesulfonic acid (CHAPS), 10 mM Tris-HCl pH 7.5, 1% dithiothreitol (DTT)), lysed for 2 h and spun at 20 000 g for 20 min. Protein concentrations of the supernatant were determined using a modified Bradford assay (Bio-Rad, Munich, Germany). Samples containing 400 mg protein were adjusted to a total volume of 400 ml, complemented with 2 ml immobilized pH gradient (IPG) buffer 3-10 and loaded on an IPGStrip (Immobiline 18 cm DryStrip 3-11NL; GE Healthcare, Freiburg, Germany). Strips were rehydrated at 30 V for 12 h. Focusing was achieved by increasing the voltage to 8000 V with a maximum current of 50 mA per strip for a total of 75 000 V hours.
After focusing strips were stored at À80 1C, for SDS-polyacrylamide gel electrophoresis (PAGE) strips were equilibrated first in 6 M urea, 2% SDS, 1% DTT, 30% glycerol in 50 mM Tris-HCl pH 8.4 for 15 min and afterward for 15 min in the same buffer but containing 2.5% iodoacetamide instead of DTT. SDS-PAGE was run overnight at 20 1C in a Hoefer DALT system using 1.5 mm 11% gels (Duracryl, Genomic solutions; gel size 24 Â 19 cm) at 80 V. Proteins were visualized by silver staining. For identification of proteins a preparative 2D gel was run in parallel with an 800 mg protein sample and subsequently stained with Coomassie brilliant blue.
Computer-aided gel analysis and quantification Gels were digitized on a GS800 scanner (Bio-Rad) for further data processing using PDQuest 2D gel analysis software (version 8.0. 035; Bio-Rad) for spot detection, gel matching and spot quantification. For evaluation of differential protein regulation a two-tailed Student's t-test was applied to optical density data for comparison between the two groups of samples. Only differences for P < 0.05 were considered as significant and were independently verified by visual inspection for correct matching. Exclusively for statistically relevant data ratios were calculated from the mean optical densities of a protein spot within corresponding groups.
Sample preparation for mass spectrometry and MALDI-TOF Protein spots were excised manually with a diameter of 2 mm and digested with trypsin (Promega Germany, Mannheim), Ziptip purified (Millipore Germany, Schwalbach) and loaded onto a matrix-assisted laser desorption/ionization (MALDI) target plate as described. 31 For protein analysis an Applied Biosystems 4700 Proteomics Analyzer with TOF/TOF Optics was used as described earlier. 32 For peptide mass fingerprint analysis a mass tolerance of 20 p.p.m. with internal calibration and one missing cleavage site were allowed. Mass spectra were searched using the Mascot engine against the SwissProt human database. As criteria for correct identification the Mascot probability score (typically > 95%) and the comparison of theoretical and experimental values for molecular mass and isoelectric point were used. This way we could clearly define the identity of the protein although sometimes more than one protein was suggested by the database search.
Subcellular fractionation, immunoblotting and immunocytochemistry
Quantitative immunoblot analysis was performed as previously described. 33, 34 In brief, centrifugation for 1 h at 100 000 g resulted in the soluble fractions. After washing the pellets twice in the same buffer (1 h 100 000 g) aliquots of the particulate fractions (P) were used for western blots. The remaining pellets were rehomogenized in lysis buffer (0.5 mM NaHCO 3 , 2.5 mM Tris-HCl, 0.5% Triton X-100, pH 8.1), incubated for 1 h at 4 1C and subsequently spun for 1 h at 100 000 g. Pellets were washed once with lysis buffer (1 h 100 000 g) and finally resuspended in gel-loading buffer. Proteins (20 mg per lane) were separated by electrophoresis on 5-20% polyacrylamide gels under fully denaturing conditions (SDS-PAGE) and transferred onto nitrocellulose. For immunodetection western blots were incubated overnight with a monoclonal prohibitin antibody (Abcam UK, Cambridge; dilution 1:1000). After extensive washing blots were incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies (anti-mouse immunoglobulin (IgG) and anti-guinea pig IgG from DAKO (dilution 1:5000, Hamburg, Germany; antirabbit IgG from Cell Signalling Germany, Frankfurt, dilution 1:5000) for 2 h and then developed using the ECL detection system (GE Healthcare). Subcellular fractionation of rat brain followed published protocols. 34 Quantification was performed with the Quantity One software from Bio-Rad.
Immunocytochemical stainings were performed as previously described. 35 Cortical primary neurons after 21 days in vitro (DIV) were fixed in 4% formaldehyde in phosphate-buffered saline (PBS) for 10 min at 37 1C. Cultures were then permeabilized with 0.25% Triton X-100 for 10 min, blocked for 1.5 h with 5% bovine serum albumin buffer and then incubated overnight with primary antibody (rabbit anti-prohibitin (1:100; Abcam), anti-ProSAP2 35 guinea pig (1:800) and mouse anti-Bassoon antibody 36 (1:1000). Coverslips were then rinsed in PBS and incubated with fluorescence-labeled antibody (Alexa-488, Alexa-568, Cy5; Molecular Probes, Leiden, the Netherlands). To visualize mitochondria cells were incubated with mitotracker 568 (Invitrogen, Karlsruhe, Germany) at a dilution of 1:2500 for 20 min at 37 1C. Thereafter cells were fixed and stained with prohibitin and ProSAP2 antibodies. The fluorescence intensity of the synaptic prohibitin staining was analyzed as the mean gray value within the selected area. This is the sum of the gray values of all the pixels in the selection divided by the number of pixels (http://rsb.info.nih.gov/ij/). The gray scale (gray values) ranges from 0 to 255.
Prohibitin overexpression in cortical primary cultures Transfection of primary neurons and analysis of synapto-dendritic phenotypes were performed essentially as previously described. 37, 38 Neurons were transfected at DIV7 and fixed with 4% paraformaldehyde (PFA) at DIV21. Stainings with synaptic and dendritic markers were performed as described above. Dendrites were analyzed with Sholl analysis using ImageJ (http://rsb.info.nih.gov/ij/). For dendritic-spine measurements, the maximum length and head width of each spine present on the dendrites was manually traced and automatically measured by computer. The green fluorescent protein (GFP) channel was taken as a readout for spine morphology because GFP-prohibitin is like GFP highly soluble and filled all spines as judged by ProSAP2 immunocytochemistry. Spine shapes were classified according to categories based on confocal laserscan pictures. Capturing of confocal images and their subsequent analysis was performed independently by two different researchers (MM, JS) unaware of the group structure. Filopodia-like and thin spines were not further differentiated.
Tissue processing for immunoblot analysis of human tissue For western blots, frozen tissue from the DPLFC of six control cases and schizophrenics was used (for demographic details see Bernstein et al.
28
). Shockfrozen tissue samples from the DPLFC were homogenized in 20 mM Tris buffer, pH 7.4, containing a protease inhibitor mixture (Roche). Detection was performed with HRP-conjugated anti-mouse secondary antibody and the ECL detection kit (GE Healthcare).
Tissue processing for immunohistochemistry of human brain The tissue preparation was performed as described earlier. 39 Briefly, brains were fixed in toto in 8% phosphate-buffered formaldehyde (pH 7.0) for at least 2 months. After embedding of the brains in Paraplast, serial coronal 20-mm-thick sections were cut on a microtome and mounted. Frontal and occipital poles were separated by coronal cuts anterior to the genu and posterior to the splenium of the corpus callosum. Frontal poles were used throughout this study. Every 50th section was stained according to the combined Nissl (cresyl violet) and myelin (Heidenhain-Wö lcke) procedure. The actual thickness of each section was then determined with a Â 100 oil immersion objective, because it is known that section thickness is decreased after histological processing. The thickness of the section was determined by focusing the upper and lower surfaces of the section and then subtracting the z axis coordinate of the lower surface from that of the upper surface. The movements in the z axis were measured with a microcator as an integral part of the Leica DM RB microscope (Leica, Gieen, Germany). The section thickness after the histological procedures was 18.9±1.0 mm (mean±s.d.)
Prohibitin immunoreactivity was detected with a monoclonal antibody (ab-1836; Abcam) using the nickel-enhanced avidin-biotin technique as described. 40 For immunohistochemical staining seven whole brain frontal sections from the prefrontal cortex of each case were used. Three of these sections were subjected to prohibitin immunohistochemistry. The sampling of the sections was performed systematically at intervals of about 2 mm in an area situated between 3.5 and 2 cm rostral of the genu of the corpus callosum. The staining protocol was performed as described earlier. 41 After preincubation of the sections with methanol/H 2 O 2 to block endogenous peroxidases and repeated washing with PBS, the antibody was applied at a working dilution of 1:50 in PBS. Thereafter the sections were processed with the avidin-biotin method (Vectastain-peroxidase kit; Vector, Burlingame, CA, USA) and the reaction product was visualized with 3,3 0 -diaminobenzidine. The color reaction was enhanced by adding 2 ml of a 0.5% (v/v) nickel ammonium sulfate solution to the diaminobenzidine. 42 Specificity of the immunoreaction was controlled by incubation with buffer and omitting the antiserum. No specific staining was observed after performing control reactions.
Morphometrical analysis
All slides were coded so that the investigators (H-G B, S Funke) were blind to diagnosis during the analysis. The section thickness after the histological procedures was 18.9±1.0 mm (mean±s.d.). A counting grid was used to define a 3D box within the thickness of the section as described earlier, 39 allowing at least 4-mm guard zones at the top and bottom of the section, and to apply a direct, 3D counting method. Prohibitin-immunoreactive neurons were counted separately in a linear probe of stacked counting boxes extending from the pial surface to the underlying white matter. 7 Laminar boundaries, which were most clearly visible at low power ( Â 6.3), were marked on the linear probes by switching back and forth between Â 6.3 and Â 40 objectives during the analysis so that cell density for each of the six layers could be calculated. Total length of the linear probe provided a measurement of cortical thickness. Values from the five linear probes were averaged to obtain a mean value of neuronal density. Eight boxes per cortical layer were counted. For selected cortical brain areas (DPLFC left and right, orbitofrontal cortex right), we examined the densities of all neurons to clarify if changes in the number of prohibitin-immunoreactive neurons are possibly due to alterations in the overall number of neurons.
Statistical analysis
Statistical analysis of immunoblotting experiments was performed with Student's t-test. Cell densities of the six cortical layers were analyzed using repeated measures ANOVA. A Bonferroni correction was applied to take into account the large number of comparisons. A P-value of < 0.05 was regarded significant. The interrater reliability as determined with a Spearman's correlation was 0.89.
Results
Subchronic ketamine changes levels of a few proteins of the rat synaptic proteome On the basis of the hypothesis that schizophrenia involves a hypofunction of the glutamatergic system in the brain we choose the rat ketamine model of schizophrenia to analyze alterations in cortical protein levels with a proteomic approach. A PSDenriched fraction was isolated biochemically and proteins were resolved using 2D gel electrophoresis. The normalized protein profiles of either control animals or the ketamine-treated group obtained from eight gels for each group showed approximately 1000 separate protein spots. A comparison among gels was not limited by the ability to match spots between case groups and normalized gels because more than 80% of all spots were matched to the reference gel allowing excellent comparison across all case groups.
After ketamine treatment as compared to salinetreated controls we could identify protein spots in PSD-enriched fraction that were up-or downregulated and after isolation identify their molecular identity by mass spectrometry. Only 12 protein spots displayed significant expression changes after subchronic ketamine treatment, with 5 spots showing a reduction and 7 spots an increase in protein levels ( Figure 1 ; Table 1 ). All 12 up-or downregulated proteins identified in the screen displayed consistent changes in abundance in all animals of the ketamine group, indicating a high fidelity of the screening procedure. All these proteins have been either identified in previous screens for the proteome of the PSD fraction or were found to interact and colocalize with postsynaptic proteins. [43] [44] [45] [46] [47] [48] [49] [50] The identified proteins form functionally related groups and are associated with metabolic pathways (that is, glutamine synthetase, nicotinamide adenine dinucleotide-ubiquinone oxidoreductase, g-enolase, lactate dehydrogenase B chain, enoyl-coenzyme A (CoA) hydrolase), cell signaling (prohibitin, voltage-dependent anion channel 2) and the cytoskeleton (transgelin 3, neurofilament-L, a-internexin, tubulin a-6 chain) or with mRNA processing (nuclear ribonucleoprotein A2/B1).
Dysregulated synaptic proteins from the left DPLFC in human chronic schizophrenia Next we sought to compare the identified synaptic protein biomarkers with human chronic schizophrenic conditions. To this end we performed the same type of screen using human post-mortem material from the DPLFC of patients suffering from chronic schizophrenia. We prepared synapse-enriched fractions and removed the excessive lipid content of human cortex prior to protein separation using 2D gel electrophoresis. This proteomic approach detected 41 protein spots with altered levels in the schizophrenia cohort ( Figure 2 ; Table 2 ). Of these 41 spots, 6 spots were downregulated (3 spots 2-fold and 3 spots > 2-fold), whereas 35 spots were upregulated (9 spots up to 2-fold and 14 spots > 3-fold). The corresponding proteins can be subdivided into six functional groups ( Figure 2 ; Table 2 ), with the two largest groups (10 proteins each) being associated with metabolism or neurotransmission/signaling, respectively. Another large group contains seven proteins that are related to cell stress/survival, further 6 spots can be associated, with biosynthesis pathways, 4 proteins with membrane trafficking processes and 4 proteins with cytoskeleton ( Figure 2 ; Table 2 ). Thus the number of proteins regulated is substantially higher than in the rat ketamine model of schizophrenia.
Two proteins, a-internexin and prohibitin, were identified in both screens. a-Internexin has been reported to be associated with PSDs 32,44-50 but in previous work we could not establish an upregulation of a-internexin protein levels in synapse-enriched fractions from dorsolateral prefrontal cortex in human chronic schizophrenia. 28 a-Internexin has also been identified in other proteomic screens, for example, in prefrontal cortex of human alcoholics 51 and it was hypothesized that phosphorylation significantly shifts its isoelectric point. Thus, the altered a-internexin protein location on gel in schizophrenics might be due to a differential phosphorylation or other posttranslational modification.
Prohibitin, a potential new biomarker for the synaptic pathology of schizophrenia Of obvious interest is the upregulation of prohibitin in both chronic schizophrenia and the rat ketamine model. The upregulation was seen in nine of the ten patients analyzed in this study (see Supplementary  Figure 1 ). Prohibitin is involved in diverse cellular processes such as cell-cycle control, senescence, apoptosis and the stabilization of mitochondrial function. 52 Interestingly, it was shown in a previous proteomic screen that 50% of all proteins regulated in total brain homogenates of chronic schizophrenic patients are mitochondrial proteins. 53 Following the identification of prohibitin as a regulated protein in both screens we therefore performed a series of experiments to confirm this finding and to validate our screening approach.
First, we demonstrated that prohibitin is present at high level in highly pure PSD-protein preparations of rat forebrain (Figure 3a) confirming its tight association with this structure. Second, immunocytochemistry in cortical primary cultures revealed that prohibitin is present in spine synapses (Figures 3b-f) and colocalizes with the presynaptic marker proteins Bassoon and ProSAP2/Shank3 (Figures 3b-f) . Moreover, prohibitin is not exclusively associated with mitochondria in neurons (Figure 3g ) and the overlap with mitochondrial structures is relatively limited. Thus, prohibitin is also a synaptic protein independent of its association with mitochondria.
Third, we showed that higher prohibitin levels are present in PSDs prepared from the cortex of rats subchronically treated with ketamine by using quantitative immunoblotting (Figure 4a ). In agreement with the proteomic data, which showed little variability, immunoblotting results were very consistent within the ketamine treatment group (n = 8) with every animal showing an upregulation as compared to controls (Figure 4b) . No upregulation was found in PSD preparations from the cerebellum of ketaminetreated rats (data not shown), indicating that the ketamine effect on the synaptic recruitment of prohibitin varies among different brain regions. Moreover, the effect of ketamine was reversible as no difference was found in comparison to control groups 2 weeks after cessation of the treatment (Figures 4a  and b) . Subsequent quantitative immunoblot analysis of PSD-enriched structures from the DPLFC of patients suffering from chronic schizophrenia showed that prohibitin protein levels are indeed elevated in PSD protein preparations of schizophrenic patients (Figures 4c and d) as compared to controls. Thus, using quantitative immunoblotting techniques we could independently confirm that Abbreviations: C, control; CoA, coenzyme A; MW, molecular weight; NADH, nicotinamide adenine dinucleotide; pI, isoelectric points; S, schizophrenic.
cortical prohibitin protein levels are upregulated in the rat ketamine psychosis model and in human chronic schizophrenia. Importantly, a subchronic treatment of rats for 2 weeks with clozapine had no effect on total (not shown) and PSD levels of prohibitin ( Supplementary Figures 2a and b) , suggesting that the treatment with neuroleptics is not causally related to the regulation of prohibitin protein levels.
Prohibitin in cortical primary cultures
Further support for the hypothesis that prohibitin association with the synapse depends upon NMDA receptor activity was found in studies using cortical primary cultures. Application of ketamine to the media with subsequent blockage of NMDA receptors for 48 h resulted in profoundly increased synaptic prohibitin immunofluorescence as compared to controls (Figures 5a-g ). This was due to the increased number of synapses containing prohibitin (Figure 5i ), whereas the total synaptic staining intensity for prohibitin was unchanged (Figure 5j ). Ketamine treatment had no influence on the number of synapses in cortical primary cultures (Figure 5h ). To address the question whether elevated prohibitin levels might induce synapto-dendritic phenotypes that resemble alterations seen in schizophrenia we then induced overexpression of a GFP-prohibitin fusion protein during development of cortical primary neurons in culture. Subsequent Sholl analysis revealed that dendrites from GFP-prohibitin transfected neurons have shorter dendrites than corresponding control neurons (Figures 6a and b) . Following prohibitin overexpression proximal dendrites are also much thinner than in GFP-control neurons (Figure 6c) . Interestingly, albeit shorter and thinner these dendrites are in their proximal segment very bushy and complex (Figures 6a and b) . The average dendritic synapse density is unchanged in GFP-prohibitin transfected neurons as compared to GFP controls (Figures 7a and b) and also the spine length was not statistically significant altered (Figure 7c) . However, the average spine width as evidenced by the GFP fluorescence is significantly enlarged (Figure 7d ). This enlargement is correlated with an increased number of spines with an irregular shape (Figure 7e ). Taken together these data indicate that some features of the synapto-dendritic alterations in certain brain regions in chronic schizophrenia are resembled by the overexpression of prohibitin in primary neurons.
Prohibitin in post-mortem brains
In the next series of experiments we examined the distribution of prohibitin immunoreactivity in paraffin-embedded human brain tissue sections from the DPLFC. It should be emphasized that paraffin sections usually do not allow to detect a synaptic localization of a given protein and we could indeed only observe a somato-dendritic staining pattern. Immunostaining of human cortical sections revealed abundant localization of prohibitin to neuronal cell bodies and dendrites in all layers of the cerebral cortex but predominantly in layers III and V (Figure 8 ). Large pyramidal and fusiform neurons were prominently labeled. Interneurons situated in layers II, IV and VI were less frequently stained (Figure 8 ). In brains of schizophrenics, we observed a different staining pattern in that the relative paucity of immunostained neurons in layer IV typically seen in controls was not detectable (Figure 8) . Moreover, staining intensity layer V pyramidal neurons appeared to be increased (Figure 8 ). This qualitative difference was substantiated by layer-specific quantitative assessment of neuronal prohibitin-immunopositive neurons. Quantitative morphometric analysis revealed that changes particularly occurred in layer IV of tissue sections from schizophrenic brains (Figure 8 ; Table 3 ). No significant changes were found in the number of cells in the different cortical layers between control and schizophrenic brains (Table 4) . Although it is at present unclear how this altered distribution relates to the synaptic localization of prohibitin at the cellular level it points to a redistribution of protein levels within the DPLFC.
Discussion
The present report is concerned with the first screen of the synaptic proteome in human chronic schizophrenia and the rat animal model of ketamineinduced psychosis. Subtle structural alterations in the thalamus, hippocampus and cortex have been associated with schizophrenia and particularly the left dorsolateral prefrontal cortex was reported to exhibit more prominent morphological abnormalities. 8, 13, 16, [54] [55] [56] To gain better insight into the molecular basis of schizophrenia a number of proteomic screens on post-mortem brain in schizophrenia therefore have been performed using these brain regions. [57] [58] [59] [60] [61] [62] In addition, corresponding screens in animal models of psychosis have been published. 63 Complementary work has been carried out with gene expression profiling of schizophrenic human brain and corresponding animal models. [64] [65] [66] [67] [68] A major shortcoming of these approaches is that although they focus on region-specific differences, they detect rather global changes in brain protein composition rather than drawing attention to the organelles that are most likely affected in schizophrenia. Thus, proteomic screens of schizophrenia-related protein alterations in protein homogenates are corrupted by the fact that the majority of cells that will be looked at are glial cells and not neurons. In particular, the important processes related to the synaptic pathology of schizophrenia might have been overlooked so far.
The PSD is a specialized protein matrix observed in primarily excitatory synapses and is crucially involved in (1) the anchoring of glutamate receptors as well as synaptic cell adhesion molecules, (2) the topological organization of signal transduction pathways and finally (3) the dynamics of synapse morphology by its connection to the spine cytoskeleton. 21, 22 Thus, the PSD has to be considered as a potential target of structural alterations in schizophrenia that will have fundamental functional consequences. In light of the reported synaptic pathology of schizophrenia 3, 10, 69, 70 we were surprised to find only a few regulated spots in the rat ketamine psychosis model, which is supposed to reflect largely the NMDA receptor hypofunction in schizophrenia. This finding is surprising as previous studies suggest numerous changes in gene expression during acute ketamine psychosis. [71] [72] [73] The small number of significant changes was not due to variations among the animals, because the 2D gel electrophoresis analyses were highly reproducible between all eight samples in each group. Previous work suggests that the mammalian postsynaptic proteome consists of a highly interconnected set of approximately more than 1000 proteins. With our approach we were able to resolve approximately 1000 protein spots, 32,43-50 from which only 12 were regulated after ketamine treatment. Thus < 2% of all proteins that could be resolved were affected by ketamine psychosis. A much higher number of altered protein spots were found in chronic human schizophrenia (41 corresponding to B4% of all resolved spots), suggesting that not only limitations of the method can account for this finding. Taken together, however, the number of regulated protein spots in synapse-enriched protein fractions is still low when compared to changes reported in gene expression studies or protein expression profiling using tissue homogenates from schizophrenia patients. A possible explanation is that 2D gel electrophoresis is capable of displaying several hundreds to a thousand proteins, whereas microarray can interrogate the entire human/mouse genome. Furthermore, 2D gel electrophoresis is not able to detect high molecular weight proteins and transmembrane proteins. Such proteins are quite often parts of synaptic signal transduction machineries that might be affected by ketamine application and chronic schizophrenia. Moreover, the high stability of synapse proteome against perturbation has been recently reported in mutant mice where the depletion of synaptic CaMKIIa by 70% did not affect the synaptic membrane protein constituent. 74 Alternatively it is therefore plausible that the alterations in gene expression or total protein levels are not necessarily reflected in altered PSD protein levels, a finding already reported for the synaptic scaffolding protein SAP97. 28 Total cellular SAP97 levels are clearly reduced in the . Merging of total synapses ((e) as red channel) with prohibitin-positive synapses ((f) as green channel) in (g) confirms that prohibitin is in part localized at synaptic sites but only at a subpopulation. (h) The number of synapses is unaltered after ketamine treatment. Statistical analysis of the number of prohibitin-positive synapses showed a highly significant increase after ketamine treatment (i) whereas no increase of prohibitin-staining intensity at synapses was detected (j). ***P < 0.001. Sholl analysis of dendrite complexity as the number of dendrites crossing the circle at the distance from the soma indicated. *P < 0.05; **P < 0.01; ***P < 0.001. (c) Dendrite diameters were measured in the most proximal first 10 mM dendritic segment from the soma using the MAP2 immunofluorescence. *P < 0.05. DPLFC of schizophrenic patients 75 but they are not altered in synaptic protein preparations. 28 The synapse is a complex cellular subcompartment with a tight local regulation of its protein content. 22, 76 It is therefore conceivable that global changes in protein expression do not necessarily affect the molecular composition of the synapse because of counteracting local regulatory events.
Not surprisingly, however, the regulated proteins were quite different in human chronic paranoid schizophrenia and the rat animal model and showed only limited overlap. A number of reasons can account for these discrepancies. Ketamine psychosis in rats is only a subchronic model of the disease that will not resemble all features of human chronic schizophrenia that in the cases included in this study lasted longer than a decade. Moreover, ketamine application albeit inducing NMDA receptor hypofunction probably only triggers certain aspects of human schizophrenia, whereas other most likely developmental malfunctions are not covered by this intervention. Finally, all patients included in this study received neuroleptic treatment, a condition not present in the animal studies.
Albeit these limitations, the present study provides a number of interesting observations. We identified many regulated protein spots that in other studies were already reported to be associated with schizophrenia. These include ATP-synthase-b subunit, 63, 77 a-internexin, 63, 77 phosphatidylethanolamine-binding protein 58 and prohibitin. 58 Noteworthy, many of the proteins found in the latter study by Clark et al. 58 to be regulated in the anterior cingulate cortex in schizophrenia were also identified in our study of the DPLFC. Future work investigating these proteins, their interactions, the genes encoding these proteins and their functions may shed light on the molecular mechanisms underlying the heterogeneous symptoms characteristic of schizophrenia.
To validate our proteomic findings we analyzed the expression of prohibitin under physiological and The spine width, however, is significantly enlarged. *P < 0.05. (e) In addition, the number of spines with an irregular morphology is higher after prohibitin overexpression. *P < 0.05. The n in (b-e) refers to the number of 50-mM-long dendritic fragments selected for analysis. For each measure more than 500 spines were quantified. pathophysiological conditions in more detail. This work showed that prohibitin not only can serve as a biomarker of the synaptic pathology in schizophrenia but might also be causally related to the disease. Of particular interest in this regard is the finding that overexpression of the protein induces phenotypes in cortical primary neurons that resemble some features of the altered synapto-dendritic cytoarchitecture in schizophrenia. The molecular basis of its overexpression phenotype is currently unknown. Importantly, prohibitin is upregulated in both chronic schizophrenia and rat ketamine psychosis and it has been implicated in a variety of different cellular processes ranging from cell-cycle control, senescence and apoptosis to the stabilization of mitochondrial proteins. 52 Even highly pure PSD preparations can contain as a contamination mitochondrial proteins. However, an abundance of mitochondria has also been the hallmark of synapses as their first ultrastructural description 50 years ago. Mitochondria have been shown to be essential for synaptic form and function 88 and it is conceivable that prohibitin might directly affect their synaptic localization and function. In nonneuronal cells prohibitin acts as a chaperone to stabilize mitochondrial proteins. 89 For nascent synapses it has been shown that the presence of mitochondria in juxtaposition to the initial contact is essential for their maturation. 88 Elevated synaptic prohibitin levels might therefore influence the maturation of synapses via their effect on mitochondrial stability adding to the synaptic pathology of schizophrenia. This idea clearly deserves further investigation. However, it should be noted that prohibitin in cortical primary neurons is not exclusively associated with mitochondria but exhibits a much more widespread distribution. Particularly its presence at synapses that are devoid of mitochondria Section from a schizophrenic patient. Note the higher density of stained cells in layer IV (small arrows). In addition, the staining intensity of neurons in layer V appears to be higher (larger arrow). Scale bar is 100 mm. Abbreviations: ACC, anterior cingulate cortex; C, control; DLP, dorsolateral prefrontal; S, schizophrenic. Significance: *P < 0.05; **P < 0.02; ***P < 0.01.
suggests that the protein fulfills functions in synaptic processes independent of its role as a mitochondrial chaperone. Although a specific role of prohibitin in synapses has not yet been established, a recent report by Rajalingam et al. 90 has shown that prohibitin is directly involved in the localization of the adhesion complex proteins cadherin and -catenin to the plasma membrane. In the absence of prohibitin, cadherin and -catenin stabilize adherens junctions and cell migration. 90 Adherens junctions are specialized zones of cell-cell contact that resemble in several aspects the connection of the pre-and postsynapse. In a neuronal context one might therefore speculate that prohibitin is a regulator of synaptic cell-cell contacts and dendrite or spine growth and limits synapse number and dendrite complexity by local signaling events.
Conclusions
Proteomic analysis of the DPLFC in human chronic schizophrenia and of the cortex in rat ketamineinduced psychosis revealed consistent changes in the synaptic proteome under both conditions. However, there was only limited overlap between both screens questioning the face validity of the rat model. Despite this limited overlap subsequent analysis confirms that prohibitins' association with synapses could establish a new biomarker for schizophrenia. We show that prohibitins' association with the synapse increases with decreased NMDA receptor activity induced by ketamine, which is in line with the observed increased levels of the protein in PSD preparations of patients suffering from chronic schizophrenia. This is consistent with the hypothesis that a hypofunction of NMDA receptor signaling is causally related to the disease. Taken together, the current study in conjunction with previous work 58 establishes prohibitin as a novel and promising candidate molecule for the pathogenesis of schizophrenia. Abbreviations: ACC, anterior cingulate cortex; C, control; DLP, dorsolateral prefrontal; S, schizophrenic.
